Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment

Symposium
Chairs: P. Levy (Grenoble, France), P. Lavie (Haifa, Israel)
Aims: This symposium will:
• identify early changes in cardiovascular function;
• identify early changes in metabolic function in the presence or absence of obesity;
• describe the major signalling pathways involved in inflammation and oxidative stress;
• evaluate the clinical value of biomarkers in the cardiovascular and metabolic fields;
• review possible therapeutic insights.
Early changes in blood pressure, vascular and heart function in obstructive sleep apnoea (OSA). Impact of treatment
J-L. Pepin (Grenoble, France)
Slide presentation
Slide presentation
Impact of obstructive sleep apnoea (OSA) on glucose metabolism
I. Harsch (Erlangen, Germany)
Slide presentationMultimedia files
Slide presentationMultimedia files
Signalling pathways in intermittent hypoxia and in obstructive sleep apnoea (OSA)
S. Ryan (Dublin, Ireland)
Slide presentationMultimedia files
Slide presentationMultimedia files